Orphan drugs make up some of the most consequential new medicines approved in the past five years. That trend is only going to accelerate, with a slate of new innovative biopharmas entering the clinic with therapies that promise to make a difference for patients who have no good options today. There’s an urgency to develop these drugs and get to market as fast as possible while maintaining a first-class development program that can withstand the rigors of regulatory scrutiny.
In this Endpoints Webinar, we’ve invited a group of experienced cancer drug developers to discuss key strategies in managing an orphan drug program.
Matthew Mollan, Ph.D., Regional Head of Operations at Catalent, will review the developability challenges of orphan oncology drugs and provide recommendations for innovator companies to consider in order to avoid common pitfalls during scale-up.